THE 30-SECOND OVERVIEW
At a glance
MK-677 and CJC-1295 are compared because both produce a sustained rise in growth hormone and IGF-1 rather than a single burst. That shared outcome hides the fact that they reach it from different receptors, by different chemistry, and with evidence records that differ by more than an order of magnitude in size. Reading the two together is useful precisely because the differences are so clean.
Two receptors
MK-677, or ibutamoren, is an orally active small molecule that mimics ghrelin at the growth hormone secretagogue receptor GHS-R1a. It is not a peptide. It is stocked as a 25mg per mL oral liquid and as 15mg tablets.
CJC-1295 is a peptide analogue of growth hormone-releasing hormone. It takes the 29-residue active fragment of GHRH, makes four substitutions to resist enzymatic breakdown, and in its full form attaches a Drug Affinity Complex, a maleimide group that couples the peptide to serum albumin after injection. It binds the GHRH receptor. The albumin coupling is what turns a peptide with a half-life of minutes into one that raised growth hormone and IGF-1 for up to 14 days after a single dose in healthy adults (Teichman et al., 2006). The two versions of the molecule, with and without the complex, are covered in CJC-1295 DAC vs no DAC.
The GHRH receptor and the ghrelin receptor converge on the same somatotroph cells, and the secretagogue class was characterised early as potentiating GHRH's effect rather than duplicating it (Fuh and Bach, 1998). That is why the two compounds appear together in combination protocols, and why comparing them as rivals misreads the pharmacology.
Both keep the pulse
The most interesting point of comparison is that neither compound flattens growth hormone into a constant level.
Ionescu and Frohman (2006) showed that pulsatile growth hormone secretion persists on top of an elevated baseline during continuous stimulation by CJC-1295, which was not an obvious result for a molecule that holds the receptor for days.
MK-677, taken once a day, produced the same kind of result by a different route. In Chapman's 1996 dose-ranging study, 25mg raised mean 24-hour growth hormone by 97 percent by enhancing the pulses that were already there: pulse height and the trough between pulses rose, and the number of pulses did not change. Copinschi (1996) found bedtime doses increased pulse frequency through additional low-amplitude pulses, with IGF-1 rising in a dose-dependent way.
So both sustain the axis without abolishing its rhythm. The mechanisms differ: CJC-1295 keeps the GHRH receptor occupied, and the pituitary keeps pulsing under that pressure; MK-677 opposes the somatostatin brake through the ghrelin receptor and lets the existing rhythm run higher.
Duration by chemistry, not by dose
CJC-1295 gets its duration from albumin binding. One injection, and the albumin-bound peptide keeps signalling for the better part of a week.
MK-677 gets its duration from being a stable small molecule with a long enough residence to be dosed once daily by mouth, which is how every published trial used it, from seven-day crossovers to Nass's two-year study (2008). A research programme that needs a sustained signal can reach it with either compound, but one does it with a weekly injection of a peptide and the other with a daily oral amount of a non-peptide. That difference in handling is often the deciding one.
The evidence records
CJC-1295's human record is small and specific. Teichman's study in healthy adults established the duration of the growth hormone and IGF-1 response after single and repeated doses. Ionescu and Frohman established that pulsatility persisted. Jetté and colleagues (2005) had earlier shown in rats that the albumin bioconjugate activates the GRF receptor on the anterior pituitary. The compound never completed a clinical development programme, and there is no long-term human safety dataset.
MK-677's record is long and includes outcomes. Beyond the dose-ranging and crossover studies, it was trialled for eight weeks in obese men (Svensson, 1998), for two years in healthy older adults (Nass, 2008), for six months in 161 hip-fracture patients (Bach, 2004), for 24 weeks in 123 more (Adunsky, 2010), and for 12 months in 563 Alzheimer's patients (Sevigny, 2008). IGF-1 rose in every one. Fat-free mass rose where it was measured. Strength, function and cognitive progression did not change, fasting glucose and insulin sensitivity moved the wrong way in several studies, and the 2010 hip-fracture trial was stopped early over a heart-failure signal. The designs are laid out in our MK-677 dosage research article, and the adverse findings in what the trials recorded as side effects.
The practical reading is that CJC-1295's data tell you what the molecule does to the axis, and MK-677's data tell you what a sustained rise in the axis does to a person over months and years. Those are different questions, and a programme should know which one it is asking.
Where each one fits
A study of GHRH-receptor pharmacology, of the effect of continuous receptor occupancy, or of injectable long-acting delivery has a CJC-1295 literature. A study of oral delivery, of sustained ghrelin-receptor agonism, or of metabolic consequences over long exposure has an MK-677 literature. A study of both receptors at once is asking the potentiation question, and on the peptide side the CJC-1295 with ipamorelin blend exists for it; MK-677 would be the oral way to supply the ghrelin-receptor half.
The takeaway
MK-677 and CJC-1295 both sustain growth hormone without flattening its pulses, one through the ghrelin receptor by mouth every day and one through the GHRH receptor by an albumin-bound injection every week. CJC-1295 has a small, clean pharmacology record. MK-677 has a large outcomes record that is consistent on hormones and cautionary on metabolism. They are not competitors for the same job.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Chapman, I. M., Bach, M. A., Van Cauter, E., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism, 81(12), 4249-4257.
2. Copinschi, G., Van Onderbergen, A., L'Hermite-Balériaux, M., et al. (1996). Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism, 81(8), 2776-2782.
3. Fuh, V. L., & Bach, M. A. (1998). Growth hormone secretagogues: mechanism of action and use in aging. Growth Hormone and IGF Research, 8(1), 13-20.
4. Svensson, J., Lönn, L., Jansson, J. O., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism, 83(2), 362-369.
5. Bach, M. A., Rockwood, K., Zetterberg, C., et al. (2004). The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. Journal of the American Geriatrics Society, 52(4), 516-523.
6. Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 146(7), 3052-3058.
7. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805.
8. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792-4797.
9. Nass, R., Pezzoli, S. S., Oliveri, M. C., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601-611.
10. Sevigny, J. J., Ryan, J. M., van Dyck, C. H., et al. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 71(21), 1702-1708.
11. Adunsky, A., Chandler, J., Heyden, N., et al. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics, 53(2), 183-189.
